慢性鼻-鼻窦炎患者实施克拉霉素联合布地奈德治疗的临床疗效观察及分析
|
摘要
目的研究对慢性鼻-鼻窦炎患者实施克拉霉素联合布地奈德治疗的临床治疗效果。方法选取2016年12月—2018年12月在该院进行治疗的100例慢性鼻-鼻窦炎患者,按照随机数字表法将患者分为对照组及观察组,各50例。对照组患者应用克拉霉素药物进行治疗,观察组患者实施克拉霉素联合布地奈德治疗,并对比两组患者的临床治疗效果、鼻窦CT检查评分及不良反应。结果观察组治疗总有效率96.00%显著高于对照组82.00%,差异有统计学意义(χ~2=5.005,P<0.05),患者治疗前,两组患者鼻窦CT检查评分比较差异无统计学意义。治疗后,两组患者鼻窦CT检查评分均低于治疗前,且观察组鼻窦CT检查评分(3.1±0.6)分低于对照组(4.7±0.8)分,差异有统计学意义(t=11.010,P<0.05),观察组不良反应发生率8.00%与对照组10.00%比较差异无统计学意义(χ~2=0.122,P>0.05)。结论克拉霉素联合布地奈德治疗通过对慢性鼻-鼻窦炎患者效果更好,提高了患者治疗效果,减少鼻塞情况,安全有效,值得临床推广应用。
Objective To study the clinical effect of clarithromycin combined with budesonide in patients with chronic rhinosinusitis.Methods One hundred patients with chronic rhinosinusitis who were treated in our hospital from December 2016 to December 2018 were randomly divided into the control group and the observation group, 50 cases each. The patients in the control group were treated with clarithromycin. The patients in the observation group were treated with clarithromycin and budesonide. The clinical effects, sinus CT scores and adverse reactions were compared between the two groups. Results The total effective rate of the observation group was 96.00%, which was significantly higher than that of the control group 82.00%,the difference was statistically significant(χ~2=5.005, P<0.05). There was no significant difference in the scores of sinus CT between the two groups before treatment. After treatment, the sinus CT scores of the two groups were lower than before treatment, and the CT score of the sinus of the observation group(3.1 ±0.6)points was lower than that of the control group(4.7±0.8)points,the difference was statistically significant(t=11.010, P<0.05). There was no significant difference between the incidence of adverse reactions in the group of 8.00% and the control group of 10.00%,the difference was statistically significant(χ~2=0.122, P>0.05). Conclusion The treatment of clarithromycin combined with budesonide is better for patients with chronic rhinosinusitis, which improves the therapeutic effect of patients and reduces the nasal congestion. It is safe and effective and worthy of clinical application.
Objective To study the clinical effect of clarithromycin combined with budesonide in patients with chronic rhinosinusitis.Methods One hundred patients with chronic rhinosinusitis who were treated in our hospital from December 2016 to December 2018 were randomly divided into the control group and the observation group, 50 cases each. The patients in the control group were treated with clarithromycin. The patients in the observation group were treated with clarithromycin and budesonide. The clinical effects, sinus CT scores and adverse reactions were compared between the two groups. Results The total effective rate of the observation group was 96.00%, which was significantly higher than that of the control group 82.00%,the difference was statistically significant(χ~2=5.005, P<0.05). There was no significant difference in the scores of sinus CT between the two groups before treatment. After treatment, the sinus CT scores of the two groups were lower than before treatment, and the CT score of the sinus of the observation group(3.1 ±0.6)points was lower than that of the control group(4.7±0.8)points,the difference was statistically significant(t=11.010, P<0.05). There was no significant difference between the incidence of adverse reactions in the group of 8.00% and the control group of 10.00%,the difference was statistically significant(χ~2=0.122, P>0.05). Conclusion The treatment of clarithromycin combined with budesonide is better for patients with chronic rhinosinusitis, which improves the therapeutic effect of patients and reduces the nasal congestion. It is safe and effective and worthy of clinical application.
引文
[1]杨雪梅,陈立.克拉霉素治疗慢性鼻窦炎52例[J].中国药业,2015,28(15):137-138.
[2]李伯臣.长期低剂量克拉霉素联合布地奈德治疗慢性鼻窦炎临床研究[J].中国药业,2013,22(12):36-37.
[3]胡凤玲,白锋波.鼻渊舒口服液联合克拉霉素治疗慢性鼻窦炎的疗效及安全性分析[J].中国药业,2015,28(18):35-37.
[4]李震,张瑞桐,苏光春,等.克拉霉素强化治疗用于慢性鼻窦炎患者的临床观察[J].中国药房,2017,28(30):4212-4215.
[5]皇甫劲.克拉霉素联合香菊胶囊对慢性鼻窦炎患者的临床疗效及安全性观察[J].中国生化药物杂志,2017,37(6):137-138,141.
[6]杨红丽,冯蓉,安丽,等.布地奈德联合克拉霉素治疗慢性鼻.鼻窦炎疗效观察以及对黏膜组织重塑的影响[J].中国耳鼻咽喉头颈外科,2017,24(2):99-102.
[7]杨冬平,杨军华,谢清兰.布地奈德联合克拉霉素治疗慢性鼻-鼻窦炎的疗效观察[J].基层医学论坛,2016,20(10):1355-1356.
[8]张伟光,李宁宁.克拉霉素治疗慢性鼻-鼻窦炎对VAS、鼻窦CT及鼻内镜评分的影响[J].中国现代医药杂志,2017,19(2):40-43.
[9]曾海鸣.小剂量克拉霉素联合布地奈德雾化吸入治疗儿童鼻窦炎的疗效观察[J].实用医技杂志,2017,24(10):1114-1116.
[10]朱金亮.布地奈德联合克拉霉素治疗慢性鼻-鼻窦炎98例[J].北方药学,2018,15(7):103-104.
[11]李富民.慢性鼻-鼻窦炎行长期小剂量克拉霉素联合鼻用激素治疗的疗效[J].中国实用医药,2016,11(22):144-145.
[12]吴军德.克拉霉素联合曲安奈德治疗慢性鼻-鼻窦炎的临床疗效[J].临床合理用药杂志,2016,9(6):98-99.
[2]李伯臣.长期低剂量克拉霉素联合布地奈德治疗慢性鼻窦炎临床研究[J].中国药业,2013,22(12):36-37.
[3]胡凤玲,白锋波.鼻渊舒口服液联合克拉霉素治疗慢性鼻窦炎的疗效及安全性分析[J].中国药业,2015,28(18):35-37.
[4]李震,张瑞桐,苏光春,等.克拉霉素强化治疗用于慢性鼻窦炎患者的临床观察[J].中国药房,2017,28(30):4212-4215.
[5]皇甫劲.克拉霉素联合香菊胶囊对慢性鼻窦炎患者的临床疗效及安全性观察[J].中国生化药物杂志,2017,37(6):137-138,141.
[6]杨红丽,冯蓉,安丽,等.布地奈德联合克拉霉素治疗慢性鼻.鼻窦炎疗效观察以及对黏膜组织重塑的影响[J].中国耳鼻咽喉头颈外科,2017,24(2):99-102.
[7]杨冬平,杨军华,谢清兰.布地奈德联合克拉霉素治疗慢性鼻-鼻窦炎的疗效观察[J].基层医学论坛,2016,20(10):1355-1356.
[8]张伟光,李宁宁.克拉霉素治疗慢性鼻-鼻窦炎对VAS、鼻窦CT及鼻内镜评分的影响[J].中国现代医药杂志,2017,19(2):40-43.
[9]曾海鸣.小剂量克拉霉素联合布地奈德雾化吸入治疗儿童鼻窦炎的疗效观察[J].实用医技杂志,2017,24(10):1114-1116.
[10]朱金亮.布地奈德联合克拉霉素治疗慢性鼻-鼻窦炎98例[J].北方药学,2018,15(7):103-104.
[11]李富民.慢性鼻-鼻窦炎行长期小剂量克拉霉素联合鼻用激素治疗的疗效[J].中国实用医药,2016,11(22):144-145.
[12]吴军德.克拉霉素联合曲安奈德治疗慢性鼻-鼻窦炎的临床疗效[J].临床合理用药杂志,2016,9(6):98-99.